21,825 Shares in Artivion, Inc. $AORT Acquired by Walleye Capital LLC

Walleye Capital LLC bought a new position in shares of Artivion, Inc. (NYSE:AORT) in the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor bought 21,825 shares of the company’s stock, valued at approximately $490,000.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Verition Fund Management LLC raised its position in shares of Artivion by 1.6% in the third quarter. Verition Fund Management LLC now owns 16,912 shares of the company’s stock valued at $716,000 after purchasing an additional 274 shares during the period. Entropy Technologies LP boosted its holdings in shares of Artivion by 6.0% during the 4th quarter. Entropy Technologies LP now owns 5,504 shares of the company’s stock worth $251,000 after buying an additional 310 shares during the period. Rockefeller Capital Management L.P. grew its stake in Artivion by 150.0% in the 4th quarter. Rockefeller Capital Management L.P. now owns 665 shares of the company’s stock valued at $30,000 after buying an additional 399 shares during the last quarter. Arizona State Retirement System grew its stake in Artivion by 4.6% in the 4th quarter. Arizona State Retirement System now owns 11,235 shares of the company’s stock valued at $512,000 after buying an additional 494 shares during the last quarter. Finally, Amundi raised its holdings in Artivion by 7.5% in the 1st quarter. Amundi now owns 7,186 shares of the company’s stock worth $263,000 after acquiring an additional 501 shares during the period. Institutional investors and hedge funds own 86.37% of the company’s stock.

Artivion Stock Up 2.8%

Shares of AORT opened at $29.22 on Friday. The company has a debt-to-equity ratio of 0.82, a quick ratio of 2.51 and a current ratio of 3.47. The company has a 50-day simple moving average of $24.28 and a 200-day simple moving average of $30.59. Artivion, Inc. has a 52 week low of $19.16 and a 52 week high of $48.25. The firm has a market capitalization of $1.42 billion, a P/E ratio of -417.33 and a beta of 1.25.

Artivion (NYSE:AORT) last released its earnings results on Thursday, August 6th. The company reported $0.13 earnings per share for the quarter. The business had revenue of $125.76 million for the quarter, compared to the consensus estimate of $119.99 million. Artivion had a positive return on equity of 6.07% and a negative net margin of 0.67%. On average, equities research analysts expect that Artivion, Inc. will post 0.45 earnings per share for the current year.

Insider Activity at Artivion

In related news, SVP Andrew M. Green sold 44,001 shares of the firm’s stock in a transaction on Thursday, June 11th. The stock was sold at an average price of $20.70, for a total value of $910,820.70. Following the completion of the transaction, the senior vice president directly owned 60,259 shares of the company’s stock, valued at $1,247,361.30. This trade represents a 42.20% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Jean F. Holloway sold 977 shares of Artivion stock in a transaction on Wednesday, August 12th. The stock was sold at an average price of $28.49, for a total transaction of $27,834.73. Following the sale, the senior vice president owned 184,118 shares in the company, valued at $5,245,521.82. This represents a 0.53% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. 6.30% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

A number of research analysts have weighed in on the stock. Weiss Ratings lowered shares of Artivion from a “sell (d+)” rating to a “sell (d-)” rating in a research report on Tuesday. Stifel Nicolaus set a $45.00 price objective on Artivion in a research note on Monday, June 1st. Canaccord Genuity Group set a $39.00 price objective on Artivion in a research note on Friday, August 7th. Citizens Jmp cut their price objective on Artivion from $53.00 to $48.00 and set a “market outperform” rating for the company in a research report on Friday, May 8th. Finally, Citigroup restated a “market outperform” rating on shares of Artivion in a research note on Tuesday, July 21st. Seven equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $44.67.

Artivion Company Profile

Artivion, Inc (NYSE: AORT) is a global medical technology company that develops, manufactures and markets implantable tissue products and surgical devices for cardiac and vascular surgery. The company’s portfolio includes biologic implants derived from human and animal tissue, such as allografts and xenografts, as well as synthetic scaffolds and surgical adhesives. These products are designed to repair, reinforce or replace damaged cardiovascular and thoracic tissues during procedures such as aortic repair, heart valve surgery and vascular reconstruction.

Originally founded in 1984 under the name CryoLife, the company rebranded as Artivion in early 2022 to reflect its broader mission in cardiovascular innovation.